Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
Publication date
10/2022Metadata
Show full item recordCitation
Wischik , C M , Bentham , P , Gauthier , S , Miller , S , Kook , K & Schelter , B O 2022 , ' Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate ' , Journal of Prevention of Alzheimer's Disease , vol. 9 , pp. 780-790 . https://doi.org/10.14283/jpad.2022.63